All News

Malar,rash,SLE, Lupus

Anifrolumab Reduces Lupus Flares

d Jack Cush, MD

Anifrolumab has been studied in two large phase 3 trials in systemic lupus erythematosus (SLE) patients; pooled data from both the TULIP-1 and TULIP-2 trials were used to show that anifrolumab reduces flares in patients with moderate to severe SLE. 

Read Article
Psoriasis, arms, PsA

IL-23 Inhibitor Tildrakizumab Effective in Psoriatic Arthritis

d Jack Cush, MD

Tildrakizumab, a monoclonal antibody targeting interleukin-23p19 studied in adults with psoriatic arthritis (PsA), was found to be superior to placebo and well tolerated without reports of uveitis, systemic fungal infections, inflammatory bowel disease, major cardiac events or death. 

Read Article
RheumNow Podcast square

RheumNow Podcast – BandAids for Rheumatologists (5.14.2021)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com - a website for rheumatologists, by rheumatologists.



We love Rheumatology!

Read Article
RNL, over, microphone

RheumNow Live 2021 Now Available for All

d Jack Cush, MD

RheumNow Live (RNL) for 2021 was held March 20 - 21 in Fort Worth, TX, and now all can partake in the meeting - by video, podcast or by signing up for Tuesday Nite Rheumatology (TNR).

Read Article
Cohort study of 4.4 million adolescents w/ 7.6 million fluoroquinolone Rxs found a 90 day LOW risk of tendon ruptures (0.47/1000 Pt yrs) or tendinitis (9.34 per 1000 person-years). These events were rare in kids and appear to be more common in adults. https://t.co/52uGZKAptc

Links:

Dr. John Cush RheumNow ( View Tweet)

DASH study: ?effect of diet on BP in 459 adults given 1) USA diet; 2) Fiber, fruits, Veggie (FFV) or 3) DASH diet. Compared to typical American diet, DASH diet (less so FFV) reduced mean SUA 0.25 mg/dl (P=.004); moreso w/ higher SUA levels https://t.co/XhCK9xp67P

Links:

Dr. John Cush RheumNow ( View Tweet)

BSRBR: Demyelinating Disease Following Anti-TNFα Therapy Analysis of patients receiving TNFi therapy in the BSRBR shows that the risk of demyelination is rare but is marginally increased by taking TNFi therapy. https://t.co/oHJXOa96Kn https://t.co/m2GpeEQxnP

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Live 2021 is now available for everyone! RNL 2021 was held March 20 - 21 in Fort Worth, TX, and now all can partake in the meeting - by video, podcast or by signing up for Tuesday Night Rheumatology (TNR). We hope to see you there! https://t.co/jaisVc2kGt https://t.co/vYHm8QGD14

Links:

Dr. John Cush RheumNow ( View Tweet)
Genomic study of 1190 vasculitis pts & 11302 controls identfied a genetic variant, rs3743841, located in an intron of the NAGPA gene, reached genome-wide significance for Kawasaki (p= 8.06x10−10) and IgA vasculitis.(p= 1.25x10−7; OR 1.47 ) https://t.co/bUX5MdmOSM

Links:

Dr. John Cush RheumNow ( View Tweet)

Today Sandoz announced that the US Supreme Court has denied Sandoz appeal for their Enbrel biosimilar (Erelzi; which is FDA approved) to be marketed in the US. This biosimilar is available out side of the US, but wont be US available till 2029. https://t.co/aABw1dpbMr

Links:

Dr. John Cush RheumNow ( View Tweet)

"Arthritis Mutilans" - worse outcome to chronic inflammatory arthritis is due to 5 disorders: 1) RA 2) Psoriatic arthritis 3) Tophaceous gout 4) polyarticular JIA 5) Multicentric reticulohistiocytosis (Ive never seen this!!) https://t.co/XYmBEW1F0R https://t.co/tGWNG9Aklw

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr. Janet Pope - Comorbidities in SLE From ACR 2019 https://t.co/1BjfVOfL4i #LupusAwarenessMonth https://t.co/apjrwa36dA

Links:

Dr. John Cush RheumNow ( View Tweet)
Increased Methotrexate Liver Disease in Psoriasis https://t.co/sEZajDIkSz

Links:

Dr. John Cush RheumNow ( View Tweet)

RNL 2021 - Assessing Psoriasis: Melodie Young, MSN, ANP-c https://t.co/ZzOnJOtKjz

Links:

Dr. John Cush RheumNow ( View Tweet)

Join us this Tuesday for Tuesday Night Rheumatology focusing on Spondyloarthritis with sessions from Dr. Nigil Haroon, Dr. Artie Kavanaugh, and Dr. Robert Wang. https://t.co/Jr6H0Yg6xs https://t.co/UXx37liLSZ

Links:

Dr. John Cush RheumNow ( View Tweet)
RNL 2021 - Spondyloarthritis Q & A Panel Discussion https://t.co/3oFZNV0XI6

Links:

Dr. John Cush RheumNow ( View Tweet)

New podcast available— BandAids for Rheumatologists. Listen on SoundCloud and wherever podcasts are available. https://t.co/AGROPnfAAi

Links:

Dr. John Cush RheumNow ( View Tweet)

RNL 2021: EULAR 2019 and ACR 2020 RA Treatment Guidelines - Dr. Alan Matsumoto Dr. Alan Matsumoto presents EULAR 2019 and ACR 2020 RA Treatment Guidelines at the 2021 RheumNow Live meeting. https://t.co/1swZIWGWKc

Links:

Dr. John Cush RheumNow ( View Tweet)

Cerecor has launched a c Phase 1b clinical trial (NCT04752371) of the human mAb CERC-007, targeting IL-18, in 12 patients with active adult onset Still’s disease (AOSD). They estimate AOSD affects 3,500 - 7,000 in the US 3,400 - 6,900 pts in Europe https://t.co/DlW1QbXOG0

Links:

Dr. John Cush RheumNow ( View Tweet)

CDC study from 33 sites, 25 states showed vaccine efficacy (against Sx COVID) in HCP was 82% with ONEdose (Pfizer, Moderna) and 94% for TWO doses (same as RCTs). The efficacy of only 1 dose (of a 2 dose COVID vax) is likely to be 70- 82%. https://t.co/uQhUmjSsRd

Links:

Dr. John Cush RheumNow ( View Tweet)

×